|
STRATA TECHNOLOGY PARTNERS RETAINED BY BTG TO AUCTION RIGHTS TO A SUBSTANTIAL OLED PATENT PORTFOLIO
18 April 2007 - BTG
| Strata Technology Partners, the London-based corporate finance advisory firm, announced today that it has been retained by BTG plc to auction the control over a substantial OLED patent portfolio via an exclusive license with prosecution, sublicensing and litigation rights in the field of information displays. |
Strata Technology Partners, the London-based corporate finance advisory firm, announced today that it has been retained by BTG plc to auction the control over a substantial OLED patent portfolio via an exclusive license with prosecution, sublicensing and litigation rights in the field of information displays. The patent portfolio incorporates fundamental structures, methods, and materials invented by Dr. Arthur Epstein , Director of The Ohio State University Institute for Magnetic and Electronic Polymers and Distinguished University Professor, and his team at The Ohio State University, together with a further development made by scientists at BTG. Sample inventions include the use of transparent cathodes in polymer OLED devices, the deployment of insulating layers between (or mixed with) the organic stack and an electrode, and fabrication based on lamination and screen-printing
http://www.btgplc.com
About: BTG
BTG is an intellectual property and technology commercialisation company that operates internationally. BTG creates value by investing in intellectual property and technology development, and in early stage ventures. We realise value through technology licensing, patent assertion and sale of equity investments. Through a multidisciplinary approach, we apply intellectual property and commercial expertise, together with specialist skills in science and technology, to create major product opportunities in the health and high tech sectors. BTG has commercialised important innovations, including Magnetic Resonance Imaging, Multilevel Cell Memory, Campath (alemtuzumab), the first monoclonal antibody treatment for chronic lymphocytic leukaemia, and recombinant Factor IX blood clotting protein. BTG operates through wholly owned subsidiaries BTG International Ltd and BTG International Inc in the UK and USA, respectively. |
More News:
• For April 2007
• From BTG
• For Polymer OLED Devices
|
